ECSP21088515A - Compuestos de pirrolidina - Google Patents

Compuestos de pirrolidina

Info

Publication number
ECSP21088515A
ECSP21088515A ECSENADI202188515A ECDI202188515A ECSP21088515A EC SP21088515 A ECSP21088515 A EC SP21088515A EC SENADI202188515 A ECSENADI202188515 A EC SENADI202188515A EC DI202188515 A ECDI202188515 A EC DI202188515A EC SP21088515 A ECSP21088515 A EC SP21088515A
Authority
EC
Ecuador
Prior art keywords
pyrrolidine compounds
compounds
pyrrolidine
formula
present
Prior art date
Application number
ECSENADI202188515A
Other languages
English (en)
Inventor
Soler Julian Priego
Blanco Celia Lafuente
Buezo Nuria Diaz
Gil Gema Consuelo Sanz
Perez Jose Antonio Martinez
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP21088515A publication Critical patent/ECSP21088515A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invención proporciona compuestos de la Fórmula (VER ANEXO)
ECSENADI202188515A 2019-06-07 2021-12-07 Compuestos de pirrolidina ECSP21088515A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19382477 2019-06-07

Publications (1)

Publication Number Publication Date
ECSP21088515A true ECSP21088515A (es) 2022-01-31

Family

ID=66821161

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202188515A ECSP21088515A (es) 2019-06-07 2021-12-07 Compuestos de pirrolidina

Country Status (25)

Country Link
US (3) US11286249B2 (es)
EP (1) EP3980409A1 (es)
JP (4) JP6940717B2 (es)
KR (3) KR102629923B1 (es)
CN (1) CN114008021B (es)
AU (1) AU2020287599B2 (es)
BR (1) BR112021023347A2 (es)
CL (1) CL2021003202A1 (es)
CO (1) CO2021016295A2 (es)
CR (1) CR20210602A (es)
DO (1) DOP2021000254A (es)
EA (1) EA202193007A1 (es)
EC (1) ECSP21088515A (es)
IL (2) IL321703B1 (es)
JO (1) JOP20210319B1 (es)
MA (1) MA56115A (es)
MX (2) MX2021014913A (es)
MY (1) MY200810A (es)
PE (1) PE20220134A1 (es)
PH (1) PH12021553062A1 (es)
SA (1) SA521431048B1 (es)
SG (1) SG11202113244UA (es)
UA (1) UA128540C2 (es)
WO (1) WO2020247429A1 (es)
ZA (1) ZA202109251B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3235992A1 (en) 2021-11-03 2023-05-11 Liang Tan Substituted phenylpropionic acid derivative and use thereof
CA3248327A1 (en) 2022-01-26 2023-08-03 Eli Lilly And Company PYRROLIDINE COMPOUNDS
EP4692073A1 (en) 2023-03-24 2026-02-11 Shanghai Jingxin Biomedical Co., Ltd. Cyclic amine derivative, and composition and use thereof
WO2024217537A1 (zh) * 2023-04-21 2024-10-24 深圳信立泰药业股份有限公司 一种叔胺类化合物及其制备方法和医药用途
EP4711355A1 (en) 2023-05-11 2026-03-18 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Crystal form of lipoprotein compound and preparation method therefor
TW202509024A (zh) 2023-05-19 2025-03-01 大陸商深圳信立泰藥業股份有限公司 一種磺醯胺類化合物及其製備方法和醫藥用途
EP4734986A1 (en) 2023-06-30 2026-05-06 Eli Lilly and Company Therapeutic uses and doses of lp(a) disrupter compounds
KR20260041100A (ko) 2023-07-21 2026-03-26 일라이 릴리 앤드 캄파니 Lp(a) 저하 활성을 갖는 피페리딘, 모르폴린 및 테트라히드로-피리다진 화합물
KR20260041097A (ko) 2023-07-21 2026-03-26 일라이 릴리 앤드 캄파니 Lp(a) 저하 활성을 갖는 피롤리딘 화합물
AU2024298640A1 (en) 2023-07-21 2026-01-22 Eli Lilly And Company Piperidine Compounds with Lp(a) Lowering Activity
WO2025024218A1 (en) 2023-07-21 2025-01-30 Eli Lilly And Company PYRROLIDINE COMPOUNDS WITH Lp(a) LOWERING ACTIVITY
CN119490445A (zh) * 2023-08-15 2025-02-21 深圳信立泰药业股份有限公司 一种酰基类化合物及其制备方法和医药用途
TW202523293A (zh) * 2023-11-17 2025-06-16 大陸商上海翊石醫藥科技有限公司 一種取代的２－（吡咯烷－３－基）乙酸的衍生物及其製備方法和用途
WO2025108255A1 (zh) * 2023-11-20 2025-05-30 上海齐鲁制药研究中心有限公司 一种多环类衍生物、其制备方法和应用
WO2025237188A1 (zh) * 2024-05-14 2025-11-20 石家庄以岭药业股份有限公司 一种LP(a)抑制剂化合物及其应用
WO2025255324A1 (en) * 2024-06-06 2025-12-11 Lapis Therapeutics, Inc. Inhibitors of lipoprotein(a) assembly
WO2026061518A1 (zh) * 2024-09-23 2026-03-26 上海京新生物医药有限公司 一种环状胺衍生物的固体形式、制备方法及药物组合物
JP7850336B1 (ja) * 2024-11-14 2026-04-22 イーライ リリー アンド カンパニー Ｌｐ（ａ）阻害剤化合物を含む経口組成物
CN121609698A (zh) * 2026-01-30 2026-03-06 山东京新药业有限公司 一种莫伐培林及中间体的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2685325B1 (fr) * 1991-12-20 1994-02-04 Adir Cie Nouveaux derives de pyrrolidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
EP1452521A4 (en) * 2001-08-17 2007-03-14 Eisai R&D Man Co Ltd CYCLIC COMPOUND AND AGONIST OF PPAR RECEPTOR
AU2003300438A1 (en) 2003-12-24 2005-08-03 Esperion Therapeutics, Inc. Ether compounds and compositions for cholesterol management and related uses
WO2005068412A1 (en) 2003-12-24 2005-07-28 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
CN101765587A (zh) * 2007-07-27 2010-06-30 弗·哈夫曼-拉罗切有限公司 作为taar配体的2-氮杂环丁烷甲胺类和2-吡咯烷甲胺类
AU2017215697A1 (en) * 2016-02-03 2018-07-05 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. N-sulfonyl benzamide derivative with heterocyclic substituent, preparation method therefor and pharmaceutical application thereof
CN112321475B (zh) 2020-11-13 2022-06-10 四川大学 一种γ-氨基酸类似物及其合成方法

Also Published As

Publication number Publication date
CN114008021A (zh) 2022-02-01
KR102477481B1 (ko) 2022-12-15
IL288174A (en) 2022-01-01
NZ782992A (en) 2025-02-28
ZA202109251B (en) 2024-04-24
IL321703B1 (en) 2026-04-01
CL2021003202A1 (es) 2022-09-09
IL288174B2 (en) 2025-12-01
MX2021014913A (es) 2022-01-18
EA202193007A1 (ru) 2022-03-25
JP6940717B2 (ja) 2021-09-29
MY200810A (en) 2024-01-16
US20260055086A1 (en) 2026-02-26
SG11202113244UA (en) 2021-12-30
JOP20210319B1 (ar) 2024-12-22
PE20220134A1 (es) 2022-01-27
US20210253559A1 (en) 2021-08-19
UA128540C2 (uk) 2024-08-07
US20220169636A1 (en) 2022-06-02
KR20220018494A (ko) 2022-02-15
KR20240014618A (ko) 2024-02-01
CN114008021B (zh) 2024-11-05
KR102720992B1 (ko) 2024-10-24
CO2021016295A2 (es) 2021-12-10
US12441714B2 (en) 2025-10-14
DOP2021000254A (es) 2022-01-16
AU2020287599A1 (en) 2022-01-06
JP2024123111A (ja) 2024-09-10
BR112021023347A2 (pt) 2022-04-12
MX2025001789A (es) 2025-03-07
JP7658014B2 (ja) 2025-04-07
WO2020247429A1 (en) 2020-12-10
CR20210602A (es) 2022-01-06
JP2021524498A (ja) 2021-09-13
AU2020287599B2 (en) 2023-10-19
KR102629923B1 (ko) 2024-01-30
MA56115A (fr) 2022-04-13
CA3140869A1 (en) 2020-12-10
IL288174B1 (en) 2025-08-01
JP2021191784A (ja) 2021-12-16
US11286249B2 (en) 2022-03-29
EP3980409A1 (en) 2022-04-13
SA521431048B1 (ar) 2024-04-28
JP2025098178A (ja) 2025-07-01
PH12021553062A1 (en) 2022-08-15
JP7508422B2 (ja) 2024-07-01
JOP20210319A1 (ar) 2023-01-30
IL321703A (en) 2025-08-01
KR20230004890A (ko) 2023-01-06

Similar Documents

Publication Publication Date Title
PH12020500655A1 (en) Compounds
MY203303A (en) Compounds
GEP20227403B (en) Compounds
CL2017002483A1 (es) Compuestos heterocíclicos como inhibidores de lsd1
BR112021024236A2 (pt) Proteínas multiespecíficas
IL288174A (en) Pyrrolidine compounds
MX2018015563A (es) Acidos de carbamoiloximetil triazol ciclohexilo como antagonistas de acido lisofosfatidico (lpa).
MX380394B (es) Compuesto novedoso de bifenilo o una sal del mismo.
EA201792021A1 (ru) Ингибитор jak
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
CO2022009260A2 (es) Composiciones farmacéuticas oftálmicas
CL2021002182A1 (es) Formulación de anticuerpos terapéuticos
MX374728B (es) MODULADORES DE ROR GAMMA (RORy).
ZA202101487B (en) Novel compounds
MX373603B (es) Activador de canales de kcnq2-5.
MY188420A (en) Crystalline forms of (s)-afoxolaner
CY1123406T1 (el) Παραγωγο τριαζολοπυραζινονης χρησιμο ως ενας ανθρωπινος pde1 αναστολεας
MX2018002898A (es) Compuestos utiles para inhibir ror-gamma-t.
CL2021002108A1 (es) Desinfectante endoscopico mejorado
JOP20200030A1 (ar) مركب خماسي الحلقة
MX2018003903A (es) Compuesto biciclico y uso del mismo para inhibicion de suv39h2.
MX2019008375A (es) Tiobenzoimidazol como fungicidas.
DOP2017000070A (es) Inhibidores cristalinos de bace
IT201900025348A1 (it) Procedimento per la sintesi di melfalan
GB201910665D0 (en) Novel form of compounds